Loading…

Rifampicin Is Not an Activator of Glucocorticoid Receptor

Rifampicin, an antibiotic widely used in tuberculosis therapy, is known to exert psychotropic side effects in some patients. Recently, rifampicin has been reported to activate the glucocorticoid receptor (GR) in human hepatocytes. Because there is evidence that increased levels of glucocorticoids ma...

Full description

Saved in:
Bibliographic Details
Published in:Molecular pharmacology 2000-04, Vol.57 (4), p.732-737
Main Authors: Herr, A S, Wochnik, G M, Rosenhagen, M C, Holsboer, F, Rein, T
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c317t-296bf8381f6f6a071476437a89985e6f06955ae2f6503cf5952e9235373bae803
cites
container_end_page 737
container_issue 4
container_start_page 732
container_title Molecular pharmacology
container_volume 57
creator Herr, A S
Wochnik, G M
Rosenhagen, M C
Holsboer, F
Rein, T
description Rifampicin, an antibiotic widely used in tuberculosis therapy, is known to exert psychotropic side effects in some patients. Recently, rifampicin has been reported to activate the glucocorticoid receptor (GR) in human hepatocytes. Because there is evidence that increased levels of glucocorticoids may induce cognitive impairment, sometimes culminating in depression, the side effects of rifampicin may result from GR activation in central nerve cells. Therefore, we used reporter gene assays to determine whether rifampicin displays glucocorticoid-like effects in human neuroblastoma SK-N-MC cells or mouse hippocampal HT22 cells. Rifampicin was unable to elicit any detectable transactivation of GR in both cell types, whereas cortisol or dexamethasone led to a potent transcriptional response. Rifampicin was also inactive in the same HepG2 cell line that was originally used to demonstrate the effect of rifampicin on GR. Moreover, rifampicin was unable to compete with dexamethasone for binding to GR. Finally, by blocking the multidrug resistance P-glycoprotein transporter (a xenobiotic extrusion pump) with verapamil or cyclosporin A, we excluded the possibility that the lack of effect by rifampicin was due to its export from the cell. Our results establish that rifampicin does not activate GR, and rule out the hypothesis that the psychotropic side effects of rifampicin treatment are a consequence of GR activation.
doi_str_mv 10.1124/mol.57.4.732
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1124_mol_57_4_732</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10727519</sourcerecordid><originalsourceid>FETCH-LOGICAL-c317t-296bf8381f6f6a071476437a89985e6f06955ae2f6503cf5952e9235373bae803</originalsourceid><addsrcrecordid>eNpNkM9LwzAcxYMobk5vnqUXb7bmmzS_jmPoHAyFoeAtZFmyRdqlpJ2y_95KBT29w_vw4H0QugZcAJDyvo5VwURRFoKSEzQGRiDHAHCKxhgTnkvF3kfoom0_MIaSSXyORoAFEQzUGKlV8KZugg37bNFmz7HLzD6b2i58mi6mLPpsXh1stDF1wcawyVbOuqavLtGZN1Xrrn5zgt4eH15nT_nyZb6YTZe5pSC6nCi-9pJK8NxzgwWUgpdUGKmUZI57zBVjxhHPGabWM8WIU4QyKujaOInpBN0NuzbFtk3O6yaF2qSjBqx_DOjegGZCl7o30OM3A94c1rXb_IOHyz1wOwC7sN19heR0szOpNjZWcXv8G_oGz1BiWw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Rifampicin Is Not an Activator of Glucocorticoid Receptor</title><source>Free Full-Text Journals in Chemistry</source><creator>Herr, A S ; Wochnik, G M ; Rosenhagen, M C ; Holsboer, F ; Rein, T</creator><creatorcontrib>Herr, A S ; Wochnik, G M ; Rosenhagen, M C ; Holsboer, F ; Rein, T</creatorcontrib><description>Rifampicin, an antibiotic widely used in tuberculosis therapy, is known to exert psychotropic side effects in some patients. Recently, rifampicin has been reported to activate the glucocorticoid receptor (GR) in human hepatocytes. Because there is evidence that increased levels of glucocorticoids may induce cognitive impairment, sometimes culminating in depression, the side effects of rifampicin may result from GR activation in central nerve cells. Therefore, we used reporter gene assays to determine whether rifampicin displays glucocorticoid-like effects in human neuroblastoma SK-N-MC cells or mouse hippocampal HT22 cells. Rifampicin was unable to elicit any detectable transactivation of GR in both cell types, whereas cortisol or dexamethasone led to a potent transcriptional response. Rifampicin was also inactive in the same HepG2 cell line that was originally used to demonstrate the effect of rifampicin on GR. Moreover, rifampicin was unable to compete with dexamethasone for binding to GR. Finally, by blocking the multidrug resistance P-glycoprotein transporter (a xenobiotic extrusion pump) with verapamil or cyclosporin A, we excluded the possibility that the lack of effect by rifampicin was due to its export from the cell. Our results establish that rifampicin does not activate GR, and rule out the hypothesis that the psychotropic side effects of rifampicin treatment are a consequence of GR activation.</description><identifier>ISSN: 0026-895X</identifier><identifier>EISSN: 1521-0111</identifier><identifier>DOI: 10.1124/mol.57.4.732</identifier><identifier>PMID: 10727519</identifier><language>eng</language><publisher>United States: American Society for Pharmacology and Experimental Therapeutics</publisher><subject>Animals ; Antibiotics, Antitubercular - pharmacology ; ATP Binding Cassette Transporter, Subfamily B - antagonists &amp; inhibitors ; Cells, Cultured ; Dexamethasone - pharmacology ; Drug Interactions ; Hippocampus - cytology ; Hippocampus - drug effects ; Humans ; Hydrocortisone - pharmacology ; Ligands ; Mice ; Neurons - drug effects ; Neurons - metabolism ; Promoter Regions, Genetic ; Receptors, Glucocorticoid - agonists ; Receptors, Glucocorticoid - metabolism ; Rifampin - pharmacology ; Transcription, Genetic - drug effects</subject><ispartof>Molecular pharmacology, 2000-04, Vol.57 (4), p.732-737</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c317t-296bf8381f6f6a071476437a89985e6f06955ae2f6503cf5952e9235373bae803</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10727519$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Herr, A S</creatorcontrib><creatorcontrib>Wochnik, G M</creatorcontrib><creatorcontrib>Rosenhagen, M C</creatorcontrib><creatorcontrib>Holsboer, F</creatorcontrib><creatorcontrib>Rein, T</creatorcontrib><title>Rifampicin Is Not an Activator of Glucocorticoid Receptor</title><title>Molecular pharmacology</title><addtitle>Mol Pharmacol</addtitle><description>Rifampicin, an antibiotic widely used in tuberculosis therapy, is known to exert psychotropic side effects in some patients. Recently, rifampicin has been reported to activate the glucocorticoid receptor (GR) in human hepatocytes. Because there is evidence that increased levels of glucocorticoids may induce cognitive impairment, sometimes culminating in depression, the side effects of rifampicin may result from GR activation in central nerve cells. Therefore, we used reporter gene assays to determine whether rifampicin displays glucocorticoid-like effects in human neuroblastoma SK-N-MC cells or mouse hippocampal HT22 cells. Rifampicin was unable to elicit any detectable transactivation of GR in both cell types, whereas cortisol or dexamethasone led to a potent transcriptional response. Rifampicin was also inactive in the same HepG2 cell line that was originally used to demonstrate the effect of rifampicin on GR. Moreover, rifampicin was unable to compete with dexamethasone for binding to GR. Finally, by blocking the multidrug resistance P-glycoprotein transporter (a xenobiotic extrusion pump) with verapamil or cyclosporin A, we excluded the possibility that the lack of effect by rifampicin was due to its export from the cell. Our results establish that rifampicin does not activate GR, and rule out the hypothesis that the psychotropic side effects of rifampicin treatment are a consequence of GR activation.</description><subject>Animals</subject><subject>Antibiotics, Antitubercular - pharmacology</subject><subject>ATP Binding Cassette Transporter, Subfamily B - antagonists &amp; inhibitors</subject><subject>Cells, Cultured</subject><subject>Dexamethasone - pharmacology</subject><subject>Drug Interactions</subject><subject>Hippocampus - cytology</subject><subject>Hippocampus - drug effects</subject><subject>Humans</subject><subject>Hydrocortisone - pharmacology</subject><subject>Ligands</subject><subject>Mice</subject><subject>Neurons - drug effects</subject><subject>Neurons - metabolism</subject><subject>Promoter Regions, Genetic</subject><subject>Receptors, Glucocorticoid - agonists</subject><subject>Receptors, Glucocorticoid - metabolism</subject><subject>Rifampin - pharmacology</subject><subject>Transcription, Genetic - drug effects</subject><issn>0026-895X</issn><issn>1521-0111</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNpNkM9LwzAcxYMobk5vnqUXb7bmmzS_jmPoHAyFoeAtZFmyRdqlpJ2y_95KBT29w_vw4H0QugZcAJDyvo5VwURRFoKSEzQGRiDHAHCKxhgTnkvF3kfoom0_MIaSSXyORoAFEQzUGKlV8KZugg37bNFmz7HLzD6b2i58mi6mLPpsXh1stDF1wcawyVbOuqavLtGZN1Xrrn5zgt4eH15nT_nyZb6YTZe5pSC6nCi-9pJK8NxzgwWUgpdUGKmUZI57zBVjxhHPGabWM8WIU4QyKujaOInpBN0NuzbFtk3O6yaF2qSjBqx_DOjegGZCl7o30OM3A94c1rXb_IOHyz1wOwC7sN19heR0szOpNjZWcXv8G_oGz1BiWw</recordid><startdate>20000401</startdate><enddate>20000401</enddate><creator>Herr, A S</creator><creator>Wochnik, G M</creator><creator>Rosenhagen, M C</creator><creator>Holsboer, F</creator><creator>Rein, T</creator><general>American Society for Pharmacology and Experimental Therapeutics</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20000401</creationdate><title>Rifampicin Is Not an Activator of Glucocorticoid Receptor</title><author>Herr, A S ; Wochnik, G M ; Rosenhagen, M C ; Holsboer, F ; Rein, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c317t-296bf8381f6f6a071476437a89985e6f06955ae2f6503cf5952e9235373bae803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Animals</topic><topic>Antibiotics, Antitubercular - pharmacology</topic><topic>ATP Binding Cassette Transporter, Subfamily B - antagonists &amp; inhibitors</topic><topic>Cells, Cultured</topic><topic>Dexamethasone - pharmacology</topic><topic>Drug Interactions</topic><topic>Hippocampus - cytology</topic><topic>Hippocampus - drug effects</topic><topic>Humans</topic><topic>Hydrocortisone - pharmacology</topic><topic>Ligands</topic><topic>Mice</topic><topic>Neurons - drug effects</topic><topic>Neurons - metabolism</topic><topic>Promoter Regions, Genetic</topic><topic>Receptors, Glucocorticoid - agonists</topic><topic>Receptors, Glucocorticoid - metabolism</topic><topic>Rifampin - pharmacology</topic><topic>Transcription, Genetic - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Herr, A S</creatorcontrib><creatorcontrib>Wochnik, G M</creatorcontrib><creatorcontrib>Rosenhagen, M C</creatorcontrib><creatorcontrib>Holsboer, F</creatorcontrib><creatorcontrib>Rein, T</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Molecular pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Herr, A S</au><au>Wochnik, G M</au><au>Rosenhagen, M C</au><au>Holsboer, F</au><au>Rein, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rifampicin Is Not an Activator of Glucocorticoid Receptor</atitle><jtitle>Molecular pharmacology</jtitle><addtitle>Mol Pharmacol</addtitle><date>2000-04-01</date><risdate>2000</risdate><volume>57</volume><issue>4</issue><spage>732</spage><epage>737</epage><pages>732-737</pages><issn>0026-895X</issn><eissn>1521-0111</eissn><abstract>Rifampicin, an antibiotic widely used in tuberculosis therapy, is known to exert psychotropic side effects in some patients. Recently, rifampicin has been reported to activate the glucocorticoid receptor (GR) in human hepatocytes. Because there is evidence that increased levels of glucocorticoids may induce cognitive impairment, sometimes culminating in depression, the side effects of rifampicin may result from GR activation in central nerve cells. Therefore, we used reporter gene assays to determine whether rifampicin displays glucocorticoid-like effects in human neuroblastoma SK-N-MC cells or mouse hippocampal HT22 cells. Rifampicin was unable to elicit any detectable transactivation of GR in both cell types, whereas cortisol or dexamethasone led to a potent transcriptional response. Rifampicin was also inactive in the same HepG2 cell line that was originally used to demonstrate the effect of rifampicin on GR. Moreover, rifampicin was unable to compete with dexamethasone for binding to GR. Finally, by blocking the multidrug resistance P-glycoprotein transporter (a xenobiotic extrusion pump) with verapamil or cyclosporin A, we excluded the possibility that the lack of effect by rifampicin was due to its export from the cell. Our results establish that rifampicin does not activate GR, and rule out the hypothesis that the psychotropic side effects of rifampicin treatment are a consequence of GR activation.</abstract><cop>United States</cop><pub>American Society for Pharmacology and Experimental Therapeutics</pub><pmid>10727519</pmid><doi>10.1124/mol.57.4.732</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0026-895X
ispartof Molecular pharmacology, 2000-04, Vol.57 (4), p.732-737
issn 0026-895X
1521-0111
language eng
recordid cdi_crossref_primary_10_1124_mol_57_4_732
source Free Full-Text Journals in Chemistry
subjects Animals
Antibiotics, Antitubercular - pharmacology
ATP Binding Cassette Transporter, Subfamily B - antagonists & inhibitors
Cells, Cultured
Dexamethasone - pharmacology
Drug Interactions
Hippocampus - cytology
Hippocampus - drug effects
Humans
Hydrocortisone - pharmacology
Ligands
Mice
Neurons - drug effects
Neurons - metabolism
Promoter Regions, Genetic
Receptors, Glucocorticoid - agonists
Receptors, Glucocorticoid - metabolism
Rifampin - pharmacology
Transcription, Genetic - drug effects
title Rifampicin Is Not an Activator of Glucocorticoid Receptor
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T15%3A03%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rifampicin%20Is%20Not%20an%20Activator%20of%20Glucocorticoid%20Receptor&rft.jtitle=Molecular%20pharmacology&rft.au=Herr,%20A%20S&rft.date=2000-04-01&rft.volume=57&rft.issue=4&rft.spage=732&rft.epage=737&rft.pages=732-737&rft.issn=0026-895X&rft.eissn=1521-0111&rft_id=info:doi/10.1124/mol.57.4.732&rft_dat=%3Cpubmed_cross%3E10727519%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c317t-296bf8381f6f6a071476437a89985e6f06955ae2f6503cf5952e9235373bae803%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/10727519&rfr_iscdi=true